Inhibiting 5-lipoxygenase prevents skeletal muscle atrophy by targeting organogenesis signalling and insulin-like growth factor-1.

Hyun-Jun KimSeon-Wook KimSang-Hoon LeeDa-Woon JungDarren Reece Williams

Published in: Journal of cachexia, sarcopenia and muscle (2022)

These results shed new light on novel drug targets and mechanisms underpinning skeletal muscle atrophy. Alox5 is a regulator and drug target for muscle atrophy, and malotilate is an attractive compound for repurposing studies to treat this disease.

Keyphrases

skeletal muscle
insulin resistance
signaling pathway
adverse drug
transcription factor
drug induced
type diabetes
emergency department
adipose tissue
growth hormone
drug discovery